TOKYO -- Fujifilm will apply for permission as soon as this fiscal year to run clinical trials on a treatment using a type of stem cell derived from adult tissue, aiming to become Japan's first company to test the cells for practical use in regenerative medicine.
The Fujifilm Holdings unit aims to start testing the therapy, aimed at patients with severe complications from leukemia treatment, in 2019, and hopes to win approval to manufacture and market the therapy in 2022. Preliminary discussions with oversight agencies are nearly complete.
